Cargando…
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
SIMPLE SUMMARY: Metastatic PC often represents a complex decision-making moment for oncologists, particularly due to the general conditions of the patients, age, and the potential toxicity of chemotherapy. Choosing the best first-line treatment is the first step towards improving survival and qualit...
Autores principales: | Di Costanzo, Francesco, Di Costanzo, Federica, Antonuzzo, Lorenzo, Mazza, Ernesto, Giommoni, Elisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856679/ https://www.ncbi.nlm.nih.gov/pubmed/36672366 http://dx.doi.org/10.3390/cancers15020416 |
Ejemplares similares
-
Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020) -
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022) -
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
por: Fukahori, Masaru, et al.
Publicado: (2023) -
Real-world comparative effectiveness of nab-paclitaxel plus
gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a
systematic review
por: Chiorean, Elena Gabriela, et al.
Publicado: (2019) -
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)